VANCOUVER, BC — August 15, 2025 — Leads & Copy — Onco-Innovations Limited has announced that over 90% of its outstanding common share purchase warrants priced at $0.60 have been exercised, resulting in an additional inflow of capital. The company believes this high conversion rate reflects strong shareholder alignment and growing market confidence in its long-term vision.
These warrant exercises, which took place over eight months, support the company’s non-dilutive financing objectives. Thomas O’Shaughnessy, CEO of Onco-Innovations, stated the warrant exercises demonstrate shareholders’ belief in the company’s strategic direction and reinforces the company’s ability to generate meaningful capital internally.
Onco-Innovations is a Canadian-based company focused on cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented technology that targets solid tumors.
Thomas O’Shaughnessy, Chief Executive Officer, Tel: + 1 888 261 8055, investors@oncoinnovations.com
Source: Onco-Innovations Limited
